{"title":"Urothelial Carcinoma Seeding at Site of Nephrostomy","authors":"Ala'a Farkouh, M. Shahait","doi":"10.48083/zvxi1252","DOIUrl":"https://doi.org/10.48083/zvxi1252","url":null,"abstract":"No abstract.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80806106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Elterman, J. Baard, M. Averbeck, M. Hassouna, S. Takahashi, I. Chibuzo, A. Sebastianelli, M. Gacci
The lower urinary tract (LUT), in particular the prostate, has been theoretically recognized as a target for SARS-CoV-2. Moreover, common pathophysiological mechanisms have been described for BPE/LUTS and COVID-19, including RAS dysregulation, androgen receptors, and MetS-related factors. These factors raise concerns about the possibility of worse urological outcomes due to BPE/LUTS progression in COVID-19 patients. The available results suggest a correlation between SARS-CoV-2 infection, exacerbation or new onset of LUTS, and semen impairment. BPE patients’ care and management have been deeply affected by COVID-19. In the midst of the pandemic, the main urological guidelines suggested postponement of BPH-related deferrable medical examinations and surgery. Telemedicine, therefore, gained attention and interest. Clinical evidence of impaired QoL or complications expedited surgical intervention. An informed consent covering the risk of COVID-19 and a negative molecular PCR within 72 hours of surgery were mandatory. A reduction in procedures under general anaesthesia was recommended. Long waiting lists accrued worldwide during the pandemic, leading to regular review of the BPE waiting lists and patients’ clinical status, encouraging the increase of minimally invasive office-based procedures, even in the post-COVID-19 era, and the improvement of telemedicine. Prospective studies are still needed to assess the course of LUTS/BPE patients after COVID-19.
{"title":"Management of Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia During and After COVID-19","authors":"D. Elterman, J. Baard, M. Averbeck, M. Hassouna, S. Takahashi, I. Chibuzo, A. Sebastianelli, M. Gacci","doi":"10.48083/jtru9739","DOIUrl":"https://doi.org/10.48083/jtru9739","url":null,"abstract":"The lower urinary tract (LUT), in particular the prostate, has been theoretically recognized as a target for SARS-CoV-2. Moreover, common pathophysiological mechanisms have been described for BPE/LUTS and COVID-19, including RAS dysregulation, androgen receptors, and MetS-related factors. These factors raise concerns about the possibility of worse urological outcomes due to BPE/LUTS progression in COVID-19 patients. The available results suggest a correlation between SARS-CoV-2 infection, exacerbation or new onset of LUTS, and semen impairment. BPE patients’ care and management have been deeply affected by COVID-19. In the midst of the pandemic, the main urological guidelines suggested postponement of BPH-related deferrable medical examinations and surgery. Telemedicine, therefore, gained attention and interest. Clinical evidence of impaired QoL or complications expedited surgical intervention. An informed consent covering the risk of COVID-19 and a negative molecular PCR within 72 hours of surgery were mandatory. A reduction in procedures under general anaesthesia was recommended. Long waiting lists accrued worldwide during the pandemic, leading to regular review of the BPE waiting lists and patients’ clinical status, encouraging the increase of minimally invasive office-based procedures, even in the post-COVID-19 era, and the improvement of telemedicine. Prospective studies are still needed to assess the course of LUTS/BPE patients after COVID-19.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84501370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. González-Padilla, R. España-Navarro, J. D. Subiela, Raj Kumar, L. G. Medina, J. Aumatell, J. M. De la Morena-Gallego, G. Cacciamani
Objective To evaluate the impact of the “Movember” awareness campaign (men’s health campaign that takes place every November) on internet search trends for information online about prostate cancer and to compare the results with those for “Pinktober” (the breast cancer awareness campaign that takes place in October) in the Spanish language as an indirect measure of its effectiveness. Methods Google Trends was used to evaluate the monthly relative search volumes (RSV) of the terms “cáncer de próstata” (prostate cancer), “cáncer de mama” (breast cancer), and “Movember” from January 2009 to December 2019 both in Spain and worldwide (in the Spanish language). Breast cancer was used as a comparator of the campaign impact. Mean increase in RSV on-campaign and off-campaign was calculated and compared using the Mann-Whitney U test and Joinpoint regression analysis to assess loss or gain of interest. Results The term “cáncer de próstata” showed a statistically significant increase during the campaign months both in Spain (17.4%; P < 0.001) and worldwide (35.4%; P < 0.001). Both “cáncer de próstata” and Movember showed a decreasing trend worldwide and in Spain, while “cáncer de mama” showed an increasing trend. Conclusion The Movember campaign generates a statistically significant increase in the search trends on “cancer de próstata” (prostate cancer) during the month of November (both in Spain and worldwide); when compared with the breast cancer campaign “Pinktober” these increases are of a lesser magnitude but still significant, suggesting that the campaign is effective beyond the English language, although the interest has been decreasing throughout the years.
目的评价“Movember”宣传活动(每年11月开展的男性健康宣传活动)对网上前列腺癌信息搜索趋势的影响，并将其结果与西班牙语“Pinktober”(每年10月开展的乳腺癌宣传活动)的结果进行比较，作为间接衡量其有效性的指标。方法利用谷歌趋势(Google Trends)对2009年1月至2019年12月在西班牙和全球(西班牙语)的“cáncer de próstata”(前列腺癌)、“cáncer de mama”(乳腺癌)和“Movember”三个词的月相对搜索量(RSV)进行评估。乳腺癌被用作运动影响的比较指标。使用Mann-Whitney U检验和Joinpoint回归分析来计算和比较活动前后RSV的平均增加，以评估兴趣的损失或获得。结果在西班牙，“cáncer de próstata”一词在竞选期间的使用频率显著增加(17.4%;P < 0.001)和全世界(35.4%;P < 0.001)。“cáncer de próstata”和“Movember”在全球和西班牙均呈现下降趋势，而“cáncer de mama”呈现上升趋势。在11月份(西班牙和世界范围内)，“胡子月”活动对“cancer de próstata”(前列腺癌)的搜索趋势产生了统计上的显著增长;与乳腺癌运动“粉红十月”相比，这些增长幅度较小，但仍然很重要，这表明该运动在英语之外也有效，尽管多年来人们的兴趣一直在下降。
{"title":"Is “Movember” an Effective Prostate Cancer Awareness Campaign Beyond the English Language? Insights From Google Trends Among Spanish Speakers","authors":"D. González-Padilla, R. España-Navarro, J. D. Subiela, Raj Kumar, L. G. Medina, J. Aumatell, J. M. De la Morena-Gallego, G. Cacciamani","doi":"10.48083/uhsi5324","DOIUrl":"https://doi.org/10.48083/uhsi5324","url":null,"abstract":"Objective To evaluate the impact of the “Movember” awareness campaign (men’s health campaign that takes place every November) on internet search trends for information online about prostate cancer and to compare the results with those for “Pinktober” (the breast cancer awareness campaign that takes place in October) in the Spanish language as an indirect measure of its effectiveness. Methods Google Trends was used to evaluate the monthly relative search volumes (RSV) of the terms “cáncer de próstata” (prostate cancer), “cáncer de mama” (breast cancer), and “Movember” from January 2009 to December 2019 both in Spain and worldwide (in the Spanish language). Breast cancer was used as a comparator of the campaign impact. Mean increase in RSV on-campaign and off-campaign was calculated and compared using the Mann-Whitney U test and Joinpoint regression analysis to assess loss or gain of interest. Results The term “cáncer de próstata” showed a statistically significant increase during the campaign months both in Spain (17.4%; P < 0.001) and worldwide (35.4%; P < 0.001). Both “cáncer de próstata” and Movember showed a decreasing trend worldwide and in Spain, while “cáncer de mama” showed an increasing trend. Conclusion The Movember campaign generates a statistically significant increase in the search trends on “cancer de próstata” (prostate cancer) during the month of November (both in Spain and worldwide); when compared with the breast cancer campaign “Pinktober” these increases are of a lesser magnitude but still significant, suggesting that the campaign is effective beyond the English language, although the interest has been decreasing throughout the years.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86749148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expert Roundtable Discussion on Penile Prosthesis Infection Prevention Measures","authors":"E. Chung, M. Gross, K. van Renterghem, J. Simhan","doi":"10.48083/gvcc5010","DOIUrl":"https://doi.org/10.48083/gvcc5010","url":null,"abstract":"No abstract.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90402794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. McClintock, Hadia Khanani, A. de Rosa, S. Leslie, N. Ahmadi, J. Fallot, P. Ferguson, H. Woo
Objectives To test the hypothesis that a randomised trial of extended pelvic lymph node dissection (ePLND) can recruit at a rate acceptable for a larger scale trial. To compare the following secondary endpoints between the 2 arms: the rate of protocol violations, the intraoperative and postoperative morbidity of ePLND, and complications, and to evaluate short-term oncological outcomes comparing biochemical recurrence, clinical recurrence, and survival between arms. Patients and Methods A pilot study will be undertaken at Chris O’Brien Lifehouse and Royal Prince Alfred Hospitals for the NODE trial. Twenty patients will be randomised 1:1 to radical prostatectomy with or withoutePLND. Eligible participants will have high-risk prostate cancer and will be scheduled for robotic radical prostatectomy. High-risk disease will be defined as in the 2019 NCCN guidelines (stage ≥ T3a, ISUP Grade Group ≥ 4 or PSA ≥ 20ng/mL). PSMA PET/CT staging not showing any extraprostatic disease will be required. Quality control measures to ensure consistent delivery of high-quality extended lymph node dissections are in place,and surgeons have been selected for their consistent ability to perform such procedures. Results The trial is currently underway. Conclusion On current available evidence, it is unclear if ePLND provides additional benefit over radicalprostatectomy.
目的验证一项扩大盆腔淋巴结清扫(ePLND)的随机试验是否能够以可接受的速率进行更大规模的试验。比较两组间的以下次要终点:方案违反率、术中和术后ePLND的发病率和并发症，并比较两组间生化复发、临床复发和生存率的短期肿瘤预后。患者和方法将在Chris O 'Brien Lifehouse和Royal Prince Alfred医院进行NODE试验的试点研究。20名患者将按1:1随机分组，接受根治性前列腺切除术，伴或不伴plnd。符合条件的参与者将患有高风险前列腺癌，并将计划进行机器人根治性前列腺切除术。高危疾病将在2019年NCCN指南中定义(分期≥T3a, ISUP分级组≥4或PSA≥20ng/mL)。PSMA PET/CT分期未显示前列腺外病变。质量控制措施，以确保持续交付高质量的延伸淋巴结清扫是到位的，外科医生已经选择了他们一贯的能力来执行这类程序。试验目前正在进行中。结论根据现有证据，尚不清楚ePLND是否比根治性前列腺切除术有更多的益处。
{"title":"Protocol for a Pilot Study of the NODE Trial, a Prospective Multicentre Randomised Trial of Extended Pelvic Lymph Node Dissection for High-Risk Prostate Cancer","authors":"G. McClintock, Hadia Khanani, A. de Rosa, S. Leslie, N. Ahmadi, J. Fallot, P. Ferguson, H. Woo","doi":"10.48083/hahe3801","DOIUrl":"https://doi.org/10.48083/hahe3801","url":null,"abstract":"Objectives To test the hypothesis that a randomised trial of extended pelvic lymph node dissection (ePLND) can recruit at a rate acceptable for a larger scale trial. To compare the following secondary endpoints between the 2 arms: the rate of protocol violations, the intraoperative and postoperative morbidity of ePLND, and complications, and to evaluate short-term oncological outcomes comparing biochemical recurrence, clinical recurrence, and survival between arms. Patients and Methods A pilot study will be undertaken at Chris O’Brien Lifehouse and Royal Prince Alfred Hospitals for the NODE trial. Twenty patients will be randomised 1:1 to radical prostatectomy with or withoutePLND. Eligible participants will have high-risk prostate cancer and will be scheduled for robotic radical prostatectomy. High-risk disease will be defined as in the 2019 NCCN guidelines (stage ≥ T3a, ISUP Grade Group ≥ 4 or PSA ≥ 20ng/mL). PSMA PET/CT staging not showing any extraprostatic disease will be required. Quality control measures to ensure consistent delivery of high-quality extended lymph node dissections are in place,and surgeons have been selected for their consistent ability to perform such procedures. Results The trial is currently underway. Conclusion On current available evidence, it is unclear if ePLND provides additional benefit over radicalprostatectomy.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85427028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Private Practice in Jordan","authors":"Zeid Abughosh","doi":"10.48083/ahop2343","DOIUrl":"https://doi.org/10.48083/ahop2343","url":null,"abstract":"No abstract.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86273386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Axell, V. Guzelburc, H. Yasmin*, B. Toia, M. Pakzad, R. Hamid, J. Ockrim, T. Greenwell
Objectives Whilst ambulatory urodynamics (aUDS) may be used as a second-stage test for patients with refractory lower urinary tract symptoms (LUTS) having non-diagnostic conventional urodynamics (UDS), the evidence for their use is limited. We have assessed the diagnostic utility and consequent symptomatic outcome of aUDS in patients with refractory LUTS. Methods A retrospective review of a prospectively acquired urodynamics database was made of 84 consecutive patients (23 male) with a median age 50.5 years (range 18 to 79) having aUDS following non-diagnostic or contradictory baseline UDS over a 12-month period. Patient demographics and urodynamic and clinical diagnosis before and after aUDS were recorded. Forty-six patients (55%) had formal urinary symptom assessment recorded before and a minimum of 6 months following aUDS-related change in management. Results Eighty-two patients (98%) had a urodynamic diagnosis made following aUDS, 57(68%) of whom had detrusor overactivity (DO); the final 2 patients had no abnormalities detected on aUDS. Change in primary UDS diagnosis occurred in 66 patients (79%). Of these 66 patients, 59 (89%) also had their clinical diagnosis changed, and 55 (83%) had their management pathway changed. There was a significant improvement in urinary symptoms 6 months following aUDS. Conclusion Change in primary diagnosis following aUDS led to a significant change in treatment care pathway and resulted in significant improvement in urinary symptoms.
{"title":"Ambulatory Urodynamic Findings Change Patient Outcomes","authors":"R. Axell, V. Guzelburc, H. Yasmin*, B. Toia, M. Pakzad, R. Hamid, J. Ockrim, T. Greenwell","doi":"10.48083/mhmi1178","DOIUrl":"https://doi.org/10.48083/mhmi1178","url":null,"abstract":"Objectives Whilst ambulatory urodynamics (aUDS) may be used as a second-stage test for patients with refractory lower urinary tract symptoms (LUTS) having non-diagnostic conventional urodynamics (UDS), the evidence for their use is limited. We have assessed the diagnostic utility and consequent symptomatic outcome of aUDS in patients with refractory LUTS. Methods A retrospective review of a prospectively acquired urodynamics database was made of 84 consecutive patients (23 male) with a median age 50.5 years (range 18 to 79) having aUDS following non-diagnostic or contradictory baseline UDS over a 12-month period. Patient demographics and urodynamic and clinical diagnosis before and after aUDS were recorded. Forty-six patients (55%) had formal urinary symptom assessment recorded before and a minimum of 6 months following aUDS-related change in management. Results Eighty-two patients (98%) had a urodynamic diagnosis made following aUDS, 57(68%) of whom had detrusor overactivity (DO); the final 2 patients had no abnormalities detected on aUDS. Change in primary UDS diagnosis occurred in 66 patients (79%). Of these 66 patients, 59 (89%) also had their clinical diagnosis changed, and 55 (83%) had their management pathway changed. There was a significant improvement in urinary symptoms 6 months following aUDS. Conclusion Change in primary diagnosis following aUDS led to a significant change in treatment care pathway and resulted in significant improvement in urinary symptoms.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81434176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Necchi, Giuseppe Basile, F. Pederzoli, M. Bandini, P. Grivas, G. Bratslavsky, P. Spiess, J. Killian, D. Lin, E. Williams, S. Ramkissoon, E. Severson, B. Alexander, J. Venstrom, P. Reddy, Kimberley McGregor, J. Elvin, A. Schrock, D. Pavlick, D. Jin, S. Trabucco, Natalie Danzinger, J. Ross
Background: Adult primary retroperitoneal sarcomas (RPSs) are a group of heterogeneous tumors with different histological subtypes. Comprehensive genomic profiling (CGP) analyses have recently provided significant insights into the biology of sarcomas by identifying genomic alterations (GAs) which could benefit from targeted therapies. Methods: RPS were evaluated by CGP using next-generation sequencing of up to 406 cancer-related genes. Tumor mutational burden (TMB) was determined on 0.83 to 1.14 mut/Mb of sequenced DNA. Finally, PD-L1 expression was determined. Results: Overall, 296 cases of primary RPS were analyzed. Liposarcoma (LPS) subtype had more GA/tumor than leiomyosarcoma (LMS) subtypes, with follicular dendritic cell sarcomas harboring the highest and synovial sarcomas the lowest. TP53 and Rb1 alterations were the highest in LMS, and CDK4/6 and MDM2 in LPS. However, both the TMB and targetable GA rates were low across subtypes. PD-L1 immunostaining was low positive in 21% and high positive in 5% of patients, respectively. Conclusions: CGP analysis revealed that potentially actionable genomic targets were rare in our cohort of RPS. Moreover, RPSs seem less likely to respond to immune checkpoint inhibitors based on putative biomarkers status. Nevertheless, genomic stratification according to histological subtypes led to description of GAs that can inform future clinical trials design.
{"title":"Primary Adult Retroperitoneal Sarcoma: A Comprehensive Genomic Profiling Study","authors":"A. Necchi, Giuseppe Basile, F. Pederzoli, M. Bandini, P. Grivas, G. Bratslavsky, P. Spiess, J. Killian, D. Lin, E. Williams, S. Ramkissoon, E. Severson, B. Alexander, J. Venstrom, P. Reddy, Kimberley McGregor, J. Elvin, A. Schrock, D. Pavlick, D. Jin, S. Trabucco, Natalie Danzinger, J. Ross","doi":"10.48083/VOGF2319","DOIUrl":"https://doi.org/10.48083/VOGF2319","url":null,"abstract":"Background: Adult primary retroperitoneal sarcomas (RPSs) are a group of heterogeneous tumors with different histological subtypes. Comprehensive genomic profiling (CGP) analyses have recently provided significant insights into the biology of sarcomas by identifying genomic alterations (GAs) which could benefit from targeted therapies.\u0000Methods: RPS were evaluated by CGP using next-generation sequencing of up to 406 cancer-related genes. Tumor mutational burden (TMB) was determined on 0.83 to 1.14 mut/Mb of sequenced DNA. Finally, PD-L1 expression was determined.\u0000Results: Overall, 296 cases of primary RPS were analyzed. Liposarcoma (LPS) subtype had more GA/tumor than leiomyosarcoma (LMS) subtypes, with follicular dendritic cell sarcomas harboring the highest and synovial sarcomas the lowest. TP53 and Rb1 alterations were the highest in LMS, and CDK4/6 and MDM2 in LPS. However, both the\u0000TMB and targetable GA rates were low across subtypes. PD-L1 immunostaining was low positive in 21% and high positive in 5% of patients, respectively.\u0000Conclusions: CGP analysis revealed that potentially actionable genomic targets were rare in our cohort of RPS. Moreover, RPSs seem less likely to respond to immune checkpoint inhibitors based on putative biomarkers status. Nevertheless, genomic stratification according to histological subtypes led to description of GAs that can inform future clinical trials design.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84554411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Kulkarni, M. Bandini, Amey Y. Patil, S. Bhadranavar, Vipin Sharma, S. Bafna, S. L. Yatam, G. Barbagli, F. Montorsi, P. Joshi
The inspection of the urethra in patients with documented or suspected urethral stricture should be carried out with small caliber ureteroscope of 6/7.5Ch. Different from flexible cystoscope (16Ch) or resectoscope (26Ch), small caliber ureteroscope allows a comprehensive evaluation of the stricture, including its length and the status of the mucosa in its proximity, without injuring or overstretching the urethra. With a small caliber ureteroscope it is also possible to cross the stricture, allowing the evaluation of the proximal urethra, the external urethral sphincter, and the bladder. A 6/7.5Ch ureteroscope also allows estimation of the real caliber of the stricture, providing a useful landmark for further treatment decisions.
{"title":"The Right Instrument for the Right Purpose: Spreading the Use of Small Caliber Ureteroscope for the Inspection of the Male and Female Urethra","authors":"S. Kulkarni, M. Bandini, Amey Y. Patil, S. Bhadranavar, Vipin Sharma, S. Bafna, S. L. Yatam, G. Barbagli, F. Montorsi, P. Joshi","doi":"10.48083/NVKO4969","DOIUrl":"https://doi.org/10.48083/NVKO4969","url":null,"abstract":"The inspection of the urethra in patients with documented or suspected urethral stricture should be carried out with small caliber ureteroscope of 6/7.5Ch. Different from flexible cystoscope (16Ch) or resectoscope (26Ch), small caliber ureteroscope allows a comprehensive evaluation of the stricture, including its length and the status of the mucosa in its proximity, without injuring or overstretching the urethra. With a small caliber ureteroscope it is also possible to cross the stricture, allowing the evaluation of the proximal urethra, the external urethral sphincter, and the bladder. A 6/7.5Ch ureteroscope also allows estimation of the real caliber of the stricture, providing a useful landmark for further treatment decisions.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87410450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mahima Tellambura, I. Thangasamy, Kwang Y. Chin, D. Murphy
Metallic ureteric stents are increasingly used for the management of malignant ureteric obstruction, a commonly encountered complication in urological and other malignancies. However, there has been limited evaluation of complications associated with these stents, including those that might arise from the use of magnetic resonance imaging (MRI). While most devices are deemed nominally “MRI-safe,” their implication on the quality of imaging produced has not been evaluated in clinical trials, and in our practice, significant artefact has been encountered with some ureteric stents—specifically, the Teleflex Rüsch DD tumour stent—compromising image quality and diagnostic certainty.
{"title":"Effect of Metallic Ureteric Stents on Magnetic Resonance Imaging: Implications for Malignant Ureteral Obstruction","authors":"Mahima Tellambura, I. Thangasamy, Kwang Y. Chin, D. Murphy","doi":"10.48083/WLVR1509","DOIUrl":"https://doi.org/10.48083/WLVR1509","url":null,"abstract":"Metallic ureteric stents are increasingly used for the management of malignant ureteric obstruction, a commonly encountered complication in urological and other malignancies. However, there has been limited evaluation of complications associated with these stents, including those that might arise from the use of magnetic resonance imaging (MRI). While most devices are deemed nominally “MRI-safe,” their implication on the quality of imaging\u0000produced has not been evaluated in clinical trials, and in our practice, significant artefact has been encountered with some ureteric stents—specifically, the Teleflex Rüsch DD tumour stent—compromising image quality and diagnostic certainty.","PeriodicalId":21961,"journal":{"name":"Société Internationale d’Urologie Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89150825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：